Patent Settlement Secures Pathway For ADVANZ PHARMA And Alvotech To Market Eylea Biosimilar

ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines, today announced that its partner Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area and the United Kingdom.

The settlement agreement allows Alvotech and its commercial partner ADVANZ PHARMA to market and sell the biosimilar as of January 1, 2026 in the United Kingdom and starting May 1, 2026 in the European Economic Area and Switzerland. The remaining terms of the agreement remain confidential.

The settlement provides ADVANZ PHARMA with a defined pathway for future commercialisation, subject to agreed terms that remain confidential.

About ADVANZ PHARMA
Partner of choice in specialty, hospital, and rare disease medicines.
ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.

For more information, visit https://www.advanzpharma.com/.